Mizuho Reiterates Buy Rating for BridgeBio Pharma, Targets $96
Mizuho maintains its buy rating on BridgeBio Pharma with a price target of $96, a 42.14% upside from the current price.
Key Points
- Mizuho reiterated its buy rating on BridgeBio Pharma with a $96 price target on June 16, 2026.
- Mizuho's $96 price target implies 42.14% upside from BridgeBio Pharma, Inc.'s ($BBIO) current $67.54 share price.
- BridgeBio Pharma, trading at $66.55, has a market cap of about $13.3 billion and a forward P/E of 137.34.
- CEO Neil Kumar sold shares in planned transactions, while analysts maintain a strong buy consensus.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mizuho has reiterated its buy rating on BridgeBio Pharma, Inc. (NasdaqGS: BBIO) with a price target of $96. This reaffirmation was made on June 16, 2026, by analyst Salim Syed. The stock is currently trading at approximately $66.55.
BridgeBio Pharma, Inc. Stock Down 11.8%
Shares of NasdaqGS:BBIO are trading around $66.55. BridgeBio Pharma has a market cap of approximately $13.3 billion and a forward P/E ratio of 137.34. The stock has experienced a 52-week low of $39.65 and a high of $84.94, with a 50-day moving average of $70.03 and a 200-day moving average of $67.32. The company's current ratio is 1.52, and its quick ratio is 1.40.
$BBIO price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
For the most recent period, BridgeBio Pharma reported revenue of about $580 million, showing a growth rate of 66.8%. The company is not yet profitable, as indicated by a net margin of -124.42%. The next earnings report is expected on August 4, 2026.
Insider Buying and Selling at BridgeBio Pharma, Inc.
CEO Neil Kumar sold 40,000 shares on June 5, 2026, at an average price of $67.88 in planned transactions. Earlier, on May 16, 2026, Kumar purchased 71,215 shares, although the price was not disclosed. President and CFO Thomas Trimarchi sold 13,651 shares at $65.08 on May 18, 2026, in a planned transaction.
Analysts Set New Price Targets
On June 16, 2026, Mizuho maintained its buy rating for BridgeBio Pharma with a $96 price target. Earlier, Canaccord Genuity initiated coverage with a buy rating and a $104 target on June 3, 2026. Citigroup initiated with a hold rating and an $82 target on May 19, 2026. The consensus among 23 analysts is a strong buy, with a mean target price of $102.71.
About BridgeBio Pharma
BridgeBio Pharma, Inc. is a biotechnology company based in Palo Alto, California. It focuses on discovering and developing treatments for genetic diseases. The company offers a range of products, including Attruby for cardiomyopathy, Fosdenopterin for molybdenum cofactor deficiency, and BBP-418 for LGMD2I. Founded in 2015, BridgeBio is led by CEO Dr. Neil Kumar and employs around 834 people.
Bottom Line
Mizuho's reiteration of a buy rating with a $96 target underscores the firm's confidence in BridgeBio Pharma's potential. The stock currently trades at $66.55, with analysts maintaining a strong buy consensus. Investors are keenly watching the company's upcoming earnings report on August 4, 2026.
Get BridgeBio Pharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BBIO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.